Piramal Pharma · NSE: PPLPHARMA · BSE: 543635
Q3 FY25 results · Oct–Dec 2024
Piramal Pharma reported revenue from operations of ₹2,204.22 crore (up 12.5% from Q3 FY24) and net profit of ₹3.68 crore (down 63.6% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,204.22 | 1,958.57 | +12.5% | 2,241.75 | −1.7% |
| Other income | 12.13 | 61.51 | −80.3% | 61.11 | −80.2% |
| Total income | 2,216.35 | 2,020.08 | +9.7% | 2,302.86 | −3.8% |
| Profit before share of associates & JVs and tax | 49.75 | 5.41 | +819.6% | 102.86 | −51.6% |
| Share of profit/(loss) of associates & JVs | 17.05 | 13.95 | 17.26 | ||
| Net profit for the period | 3.68 | 10.11 | −63.6% | 22.59 | −83.7% |
| EPS, basic (₹) | 0.03 | 0.08 | −62.5% | 0.17 | −82.4% |
| Net margin (%) | 0.2 | 0.5 | 1.0 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,248.32 | 1,024.14 | +21.9% | 1,284.39 | −2.8% |
| Other income | 24.70 | 33.11 | −25.4% | 106.38 | −76.8% |
| Total income | 1,273.02 | 1,057.25 | +20.4% | 1,390.77 | −8.5% |
| Profit before tax | 159.41 | 89.66 | +77.8% | 275.71 | −42.2% |
| Net profit for the period | 118.80 | 74.34 | +59.8% | 210.06 | −43.4% |
| EPS, basic (₹) | 0.90 | 0.56 | +60.7% | 1.59 | −43.4% |
| Net margin (%) | 9.5 | 7.3 | 16.4 |
Consolidated
- Filed with BSE
- 28 Jan 2025, 21:10 IST
- Board meeting
- 28 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Jan 2025, 21:10 IST
- Board meeting
- 28 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE